Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D06BCG
|
||||
Former ID |
DNC014098
|
||||
Drug Name |
EUSYNSTYELAMIDE B
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Canonical SMILES |
C1=CC2=C(C=C1Br)NC=C2CC3(C(C(N(C3=O)CCCCN=C(N)N)(C(=O)N<br />CCCCN=C(N)N)O)C4=CNC5=C4C=CC(=C5)Br)O
|
||||
InChI |
1S/C32H40Br2N10O4/c33-19-5-7-21-18(16-42-24(21)13-19)15-31(47)26(23-17-43-25-14-20(34)6-8-22(23)25)32(48,27(45)39-9-1-2-10-40-29(35)36)44(28(31)46)12-4-3-11-41-30(37)38/h5-8,13-14,16-17,26,42-43,47-48H,1-4,9-12,15H2,(H,39,45)(H4,35,36,40)(H4,37,38,41)/t26-,31+,32+/m1/s1
|
||||
InChIKey |
AFCHPUCHYPXZGZ-GWTOPCPNSA-N
|
||||
Target and Pathway | |||||
Target(s) | Nitric-oxide synthase, brain | Target Info | Inhibitor | [1] | |
BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
KEGG Pathway | Arginine and proline metabolism | ||||
Metabolic pathways | |||||
Calcium signaling pathway | |||||
Phagosome | |||||
Circadian entrainment | |||||
Long-term depression | |||||
Salivary secretion | |||||
Alzheimer's disease | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
NetPath Pathway | EGFR1 Signaling Pathway | ||||
PANTHER Pathway | CCKR signaling map ST | ||||
PathWhiz Pathway | Arginine and Proline Metabolism | ||||
Reactome | ROS production in response to bacteria | ||||
Nitric oxide stimulates guanylate cyclase | |||||
WikiPathways | Monoamine Transport | ||||
Myometrial Relaxation and Contraction Pathways | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
Spinal Cord Injury | |||||
Alzheimers Disease | |||||
Effects of Nitric Oxide | |||||
Serotonin Transporter Activity | |||||
References | |||||
REF 1 | J Nat Prod. 2009 Jun;72(6):1115-20.Eusynstyelamides A, B, and C, nNOS inhibitors, from the ascidian Eusynstyela latericius. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.